In addition, intratumor heterogeneity (ITH), tumor VHL status, CTLA4 methylation levels, age, chromosomal changes, etc., are also important factors for predicting PD1/PD-L1 efficacy [156, 162–165]. This evidence concerns the gene CTLA4 and neoplasm.